Glaucoma is a serious eye disease that affects a large number of people and potentially leads to permanent visual impairment. Currently, the first-line therapy is the use of topical medications in an attempt to control intraocular pressure levels and prevent further damage to ganglion cells. Over the decades, a number of agents have been introduced; most recently, the development of fixed combination therapies has signalled a new era in treating glaucoma. Although these formulations provide advantages in terms of convenience and increased quality of life, they are also associated with certain drawbacks. The novel fixed combination of latanoprost 0.005% and timolol 0.5% has been studied extensively, and overall this medication has proved effective in controlling symptoms and has become a viable option for the treatment of glaucoma.
Glaucoma is a progressive optic disc neuropathy that has become one of the leading causes of irreversible vision loss worldwide. 1 It is characterised by optic disc damage and functional losses in the visual field, and is associated with an elevated intraocular pressure (IOP). If left untreated, glaucoma will cause progressive injury to retinal ganglion cells and their axons, damaging the optic nerve and ultimately leading to permanent blindness (see Figure 1 ). In the US, over 2 million adults suffer from glaucoma, and with a growing ageing population this number is expected to rise to over 3 million by 2020. 2 Estimates of the incidence of glaucoma around the world have shown comparable or higher prevalence depending on the region investigated. 3 Due to the severe consequences of glaucoma, early treatment is critical for preventing further disease progression. However, with no dramatic or painful symptoms, early detection is challenging. Once diagnosed, treatment is administered to reduce the IOP to an acceptable level in an attempt to minimise further damage.
Currently, topical medication is the first-line therapy against this disease, followed by laser trabeculoplasty and/or surgery. 4 Specifically, prostaglandin analogues (PGAs) have become the firstline agents in glaucoma treatment due to their potency and safety. 5 However, it was recently found that nearly 40% of patients require two or more medications to achieve a modest target IOP reduction. 6 As a result, fixed or unfixed combination therapies are now often used in the management of glaucoma and are recommended when single agents prove inadequate for reaching acceptable IOP levels.
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History of Glaucoma Therapies
Research and development of fixed combinations of glaucoma treatments began as early as the 1960s. Nevertheless, the introduction of new medications since that time has been hindered by many issues, including the different pharmacokinetics of the various drugs, the cumulative nature of adverse effects when using multiple products and the potential negative drug-drug interactions. 8 To be a viable treatment option for glaucoma, a fixed combination must show a greater reduction in IOP than either of the two component drugs as monotherapies and similar efficacy and safety profiles to the concomitant use of the two drugs.
Despite these obstacles, several fixed-dose combination therapies have emerged over the past few decades. Originally, adrenergic and cholinergic agents were the only classes of drug available for topical treatment and, during that time, it was found that the IOP-reducing effects of these drugs were additive. 9, 10 Furthermore, a number of patients required both medications to adequately control their disease; as a result, interest arose in combining the two components.
Pilocarpine/epinephrine was the first fixed combination to be available commercially, in the early 1970s. Since then, the β-blocker timolol has been introduced and has become the first-line treatment for glaucoma, leading to the development of such combinations as pilocarpine/timolol and epinephrine/timolol in the 1980s. 11, 12 As research progressed, PGAs overtook timolol as first-line therapy due to their potency and safety. However, β-blockers remain the most popular class of drug for both fixed and unfixed adjunctive therapy 
Advantages of Fixed Combination Therapy
Although in general combining therapies has proved effective in glaucoma over the years, there are certain advantages to using a pre-prepared fixed combination treatment. The primary benefit of these medicines is convenience, as a single drug can replace numerous bottles and multiple drops at various times of day. This reduces the burden of therapy and improves patient quality of life.
Ease of medication administration is also associated with better compliance, which is important since adherence to a treatment regime is crucial for its success.
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In addition to improving convenience, using fewer drops also avoids exposing the ocular surface to excessive preservatives such as benzalkonium chloride, which has been associated with toxicity to the eye. 
Efficacy of the Fixed Combination of Latanoprost 0.005% and Timolol 0.5%
The fixed combination of latanoprost 0.005% and timolol 0.5% The results showing the effect of the fixed combination therapy on IOP in the three groups are summarised in Table 2 . 4 Both previous monotherapy groups showed statistically significant improvements in IOP levels compared with baseline after switching to the fixed combination treatment. These differences were seen at all three timepoints after one and three months of follow-up. For the previous latanoprost group, the mean diurnal IOP reduced by 5.48mmHg were not statistically significant and three patients developed an IOP higher than the target. 4 Based on these findings, it is advisable for patients with inadequate IOP control with monotherapy to switch to the fixed combination treatment. Furthermore, patients already exhibiting adequate IOP levels with concomitant medications may benefit from a change to the fixed therapy as it could lead to an improved quality of life and better compliance due to its simpler treatment schedule. However, if the new treatment fails to maintain target IOP levels in these patients during follow-up, a return to the concomitant treatment should be made.
Disadvantages of Fixed Combination Therapy
As with any type of medication, there are disadvantages associated with the use of fixed combination topical IOP-lowering drugs. First, there is no clear evidence confirming the superiority of such fixed combinations; in fact, at certain time-points, fixed combinations have appeared less effective than their individual components.
Furthermore, when using fixed combinations physicians cannot individualise treatment by varying the doses of the components. For instance, some patients may benefit from a timolol 0.25% solution, but all fixed solutions contain timolol 0.5%, leading to over-dosing in these patients. Similarly, the drugs cannot be split to optimise treatment times. These fixed combinations are also limited by the fact that prostaglandin medications are best administered in the evening whereas β-blockers are recommended for morning
Treatment of Glaucoma with the Fixed Combination of Latanoprost 0.005% and Timolol 0.5% 
Summary and Conclusion
Glaucoma is a severe eye disease that exhibits progressive loss of ganglion cells and may eventually lead to permanent visual impairment. Currently, the only effective means to manage this disease is by maintaining an acceptable IOP level; the first-line treatment used to accomplish this is the administration of drugs. Most recently, the introduction of fixed combination therapies, such as the fixed combination of latanoprost 0.005% and timolol 0.5%, has allowed patients to receive therapy in a more convenient manner than previous medication regimens, thereby improving their quality of life and making it easier to comply with the treatment schedule. In the majority of cases, this medication has proved effective and has become a viable option for the treatment of glaucoma. n 
